熱門資訊> 正文

Biofrontera报告第四季度收入增长并扭亏为盈

2026-03-20 03:18

Biofrontera (BFRI) reported record Q4 2025 revenue of $17.1M, up 36% year-over-year.
Gross margin surged to 82.4%, driven by improved cost structure after its transaction with Biofrontera AG.
The company posted Q4 net income of $5.6M, compared to a loss in the prior year.
Management expects continued growth and targets profitability and cash flow breakeven in 2026.

More on Biofrontera

Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Biofrontera sees Q4 2025 net sales of about $17M to $17.5M
Seeking Alpha’s Quant Rating on Biofrontera
Historical earnings data for Biofrontera
Financial information for Biofrontera

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。